Backman named associate director for research technology at Northwestern

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Vadim Backman was named associate director for Research Technology and Infrastructure at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

In addition to this new role, Backman, the Walter Dill Scott Professor of Biomedical Engineering at the McCormick School of Engineering and Applied Sciences, will continue to serve as leader of the Cancer and Physical Sciences Program at the Lurie Cancer Center.

As associate director, Backman will oversee Lurie Cancer Center’s infrastructure for interdisciplinary programs and initiatives, which include the center’s 16 Shared Resources that foster basic, clinical and translational research. He will also lead the development of innovative tools, technologies and services to support emerging disciplines across the cancer center.

Backman succeeds Milan Mrksich, the Henry Wade Rogers Professor, who was recently named Northwestern University’s interim vice president for research.

An expert in biomedical optics, Backman has developed numerous imaging technologies. Through his nanocytology technique, he developed a simple, easy-to-use test for diagnosing multiple forms of cancer at the earliest stage of disease formation. He leads Northwestern’s new Center for Physical Genomics and Engineering, focused on the entirely new field using optical imaging and computational genomics to reprogram the genome’s chromatin, which regulates gene expression.

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login